PHAXIAM Therapeutics
L. Diana Piedrahita is a Research Scientist at ERYTECH Pharma since March 2018, previously holding the position of Assistant Research Scientist. In addition to this role, L. Diana Piedrahita serves as an Associate Partner at Time for the Planet, an organization aiming to mobilize 1 billion euros to establish 100 startups focused on combating climate change. Prior experience includes roles as a Clinical Trial Assistant at ERYTECH Pharma and Assistant Researcher at the Instituto Colombiano de Medicina Tropical, where L. Diana Piedrahita pursued a PhD in Biology with a research focus on dengue. Earlier positions include Junior Researcher at the University of Wisconsin-Madison and Research Assistant at Grupo de Inmunovirología - Universidad de Antioquia. L. Diana Piedrahita holds a PhD in Biology from Universidad de Antioquia and a degree in Microbiology and Bioanalysis, specializing in Virology, from the same institution.
PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.